TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast and colon cancer.

OVERVIEW OF ACTIVITY

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of head and neck cancers and thyroid cancer.

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY
In 2015 in the United States alone, it is estimated that 220,800 new cases of prostate cancer (PC) will occur. With an estimated 27,540 deaths in 2015, PC is the second-leading cause of cancer death in men. The disease has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PC is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY
In 2015 in the United States alone it is estimated that 220,800 new cases of prostate cancer (PC) will occur. With an estimated 27,540 deaths in 2015, PC is the second-leading cause of cancer death in men. The disease has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PC is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.